| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | epigallocatechin-3-monogallate | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |